Skip to content

Gut Microbiota and Color-rectal Cancer.

Gut Microbiota-based Tool for the Detection of Color-rectal Cancer in Positive Patients for the Fecal Occult Blood Test.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04662853
Acronym
CCR-microbiota
Enrollment
153
Registered
2020-12-10
Start date
2017-01-17
Completion date
2021-07-31
Last updated
2020-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Colo-rectal Cancer, Diagnoses Disease, Intestinal Disease, Microbiota-related Disease

Keywords

Diagnosis improvement, Early diagnosis, Mathematical modelling, Gut microbiota, Colonoscopy

Brief summary

This clinical trial is focused in the development of a screening test for the people at risk of colo-rectal cancer (aged more than 50 years old), valid and safe, improving the screening prognosis increasing the sensitivity and sensitive as compared with the current method, fecal occult blood.

Detailed description

Colo-rectal cancer (CCR) is one of the most prevalent cancers in developed countries. Several studies suggest that the CCR may be related with changes in the gut microbiota. This clinical trial is focused in the development of a screening test for the people at risk of CCR (aged more than 50 years old), valid and safe, improving the screening prognosis. The main potential improvement lies in the fact that the proposed method is more specific and sensitive than the current method, fecal occult blood. It aims to distinguish whether the positive results for fecal occult blood test is due to fissures, not related with CCR (which are positive for fecal occult blood, false positive) or was caused by a cancer-related lesion. The methodology derived will also improve the sensitive as sometimes the polyps do not leak blood. Based in the previous differences found in the gut microbiota composition related with CCR for several research groups, the gut microbiota composition will be used as diagnosis tool.

Interventions

DIAGNOSTIC_TESTGut microbiota determination from feces samples.

Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.

Sponsors

Reina Sofia University Hospital
CollaboratorUNKNOWN
Junta de Andalucia
CollaboratorOTHER_GOV
Maimónides Biomedical Research Institute of Córdoba
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

-Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain).

Exclusion criteria

-The consumption of antibiotic within the previous month to inclusion in the study.

Design outcomes

Primary

MeasureTime frameDescription
Gut-microbiota-based color-rectal cancer diagnosis.A week before colonoscopy.Determination of the gut microbiota composition by 16S metagenomic, data analysis and building of a mathematical model to test the potential use of the gut microbiota architecture as biomarker to color-rectal cancer prognosis in patients with positive results in fecal occult blood test.

Secondary

MeasureTime frameDescription
Colonoscopy clinical results.At week 2.Prevalence of the different color-rectal cancer lessions.
Characteristic of the population.A week before colonoscopy.The characteristic of the population includes gender (man/woman), age (years), weight in kilograms and height in meters (weight and height will be combined to report BMI in kg/m\^2), which will be used to check for any association with the prevalence of the different color-rectal cancer lesions.
Dietary habitsA week before colonoscopy.The dietary habits will be assessed by a questionnaire and will be used to check for any association with the prevalence of the different color-rectal cancer lessions.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026